GlassScriptPhysician profile
Diana Itacy
NPI 1245706530
$1,523.76
in general payments reported to CMS, 2019-2025
15 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $211 · 2023: $379 · 2024: $412 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.03 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $263.92 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $176.17 | 2022-2025 | Clonoseq |
| Stemline Therapeutics INC. | $152.92 | 2024 | Elzonris |
| Beigene USA, INC. | $132.67 | 2024 | Brukinsa |
| Genmab U.S., INC. | $123.80 | 2023 | Epkinly |
| Epizyme, INC. | $120.86 | 2021 | |
| Janssen Biotech, INC. | $110.79 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $106.97 | 2022 | |
| Astellas Pharma US INC | $99.00 | 2023 | |
| Incyte Corporation | $62.75 | 2022-2025 | Monjuvi, Jakafi |
| Alexion Pharmaceuticals, INC. | $62.61 | 2025 | Ultomiris |
| Abbvie INC. | $41.07 | 2025 | |
| Sobi, INC | $28.62 | 2024 | |
| Morphosys, US INC. | $22.40 | 2022 | |
| Merck Sharp & Dohme LLC | $19.21 | 2025 | Recarbrio, Zerbaxa, Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Itacy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.